// App-Quantinova.ai

P015 : Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials

Researchers

Presenter

  • Laura Julian

Principal Investigators

  • Anthony Traboulsee

  • Douglas L. Arnold

  • Amit Bar-Or

  • Giancarlo Comi

  • Gavin Giovannoni

  • Hans-Peter Hartung

  • Stephen L Hauser

  • Ludwig Kappos

  • Fred Lublin

  • Krzysztof W. Selmaj

  • Shibeshih Belachew

  • Corrado Bernasconi

  • Regine Buffels

  • Wei Wei

  • Eva Havrdova

Medical Centers

  • The University of British Columbia, Vancouver, BC, Canada

  • Montreal University, Montreal, QC, Canada

  • NeuroRx Research, Montreal, QC, Canada

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • University Hospital San Raffaele, Milan, Italy

  • Queen Mary University of London, London, United Kingdom

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • University of California, San Francisco, San Francisco, CA

  • Bern University Hospital and University of Bern, Bern, Switzerland

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • 12Medical University of Łódź Poland

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • Charles Univ and VFN, Prague, Czech Republic

Locations

  • Canada

  • United States

  • Italy

  • United Kingdom

  • Germany

  • Switzerland

  • Poland

  • Czech Republic

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Ocrelizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved